Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.35 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA6 | P23280 | 6/20 | 0.35 |
| ▸ | CA5A | P35218 | 6/20 | 0.35 |
| ▸ | CA7 | P43166 | 6/20 | 0.35 |
| ▸ | CA9 | Q16790 | 6/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.35 |
| ▸ | CA4 | P22748 | 5/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | CA3 | P07451 | 5/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399722 | 0.76 | ENPP2 (0.50) | TTRENPP2CCR2 | |
| SCHEMBL2413125 | 0.75 | HSD11B1 (0.40) | COMTCA12CA1CA2CA6 | |
| Water SCHEMBL28038773 | 0.73 | COMT (0.35) | COMTCA12CA1CA2CA6 | |
| SCHEMBL2414928 | 0.72 | ENPP2 (0.53) | CA1CA2ENPP2 | |
| SCHEMBL1526272 | 0.71 | ENPP2 (0.42) | ENPP2 | |
| SCHEMBL28039072 | 0.70 | ALDH1A1 (0.51) | COMTCTSS | |
| SCHEMBL2415595 | 0.69 | COMT (0.43) | COMTCA12CA1CA2CA6 | |
| SCHEMBL841820 | 0.68 | TP53 (0.42) | CCR2 | |
| SCHEMBL16506192 | 0.67 | KMO (0.63) | COMTCA12CA1CA2CA6 | |
| SCHEMBL19618050 | 0.66 | KMO (0.48) | COMTCA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | TTR 945/4885COMT 2769/4885CA12 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.